[Treatment of platinum-resistant ovarian cancer].
Onishi
Yoshitaka
Y
Department of Obstetrics & Gynecology, Kagoshima City Hospital.
Nakamura
Toshiaki
T
Hatae
Masayuki
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000009:adverse effects / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D004249:DNA Damage / Q000187:drug effects; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D000077146:Irinotecan; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D043823:Taxoids; D000077143:Docetaxel; D005047:Etoposide; D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin